THE DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT. MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION.

No abstract is available for this paper.

• Publication year

  1965

• Venue

  Journal of Laboratory and Clinical Medicine

• Publication date

  1965-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 14281368
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THE ASSAY OF UROKINASE PREPARATIONS FOR CONTAMINATION WITH THROMBOPLASTIC MOIETIES.

  1965cited by this paper
• PARTIAL PURIFICATION AND PROPERTIES OF THE PLASMINOGEN ACTIVATOR FROM PIG HEART.

  1964cited by this paper
• ABNORMAL PLASMINOGEN-PLASMIN SYSTEM ACTIVITY (FIBRINOLYSIS) IN PATIENTS WITH HEPATIC CIRRHOSIS: ITS CAUSE AND CONSEQUENCES.

  1964cited by this paper
• ASSAY OF PLASMA THROMBOLYTIC ACTIVITY WITH FLUORESCEIN-LABELED CLOTS.

  1964cited by this paper
• The purification and properties of human plasminogen.

  1964cited by this paper
• ASSAY OF UROKINASE PREPARATIONS WITH THE SYNTHETIC SUBSTRATE ACETYL-L-LYSINE METHYL ESTER.

  1964cited by this paper
• Interaction of Heparin with Fibrinolysis

  1963cited by this paper
• Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. III. Demonstration of abnormal clot structure by electron microscopy.

  1962cited by this paper
• Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.

  1962cited by this paper
• Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products.

  1962cited by this paper
• Fibrinolytic mechanisms and the development of thrombolytic therapy.

  1962cited by this paper
• Urokinase Excretion in Man: A Method of Determination and Consideration of its Significance

  1961cited by this paper
• A Comparison of the Fibrinolytic and Fibrinogenolytic Effects of Plasminogen Activators and Proteolytic Enzymes in Plasma

  1961cited by this paper
• The biochemistry and physiology of urokinase.

  1960cited by this paper
• Studies on the thrombolytic activity of human plasma.

  1960cited by this paper
• The maintenance of a sustained thrombolytic state in man. I. Induction and effects.

  1959cited by this paper
• Studies on enhanced fibrinolytic activity in man.

  1959cited by this paper
• The mechanism of clot dissolution by plasmin.

  1959cited by this paper
• The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders.

  1959cited by this paper
• Fibrinolysis and fibrinolytic activity in man.

  1959cited by this paper
• The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase.

  1959cited by this paper
• xi-Aminocaproic acid: an inhibitor of plasminogen activation.

  1959cited by this paper
• The clearance of heterologous protein from the circulation of normal and immunized man.

  1958cited by this paper
• Clotting deviations in man during cardiac bypass: fibrinolysis and circulating anticoagulant.

  1958cited by this paper
• Urokinase an activator of plasminogen from human urine. I. Isolation and properties.

  1957cited by this paper
• The fibrin plate method for estimating fibrinolytic activity.

  1952cited by this paper

• Treatment of acute pulmonary embolism: Looking back and looking ahead.

  2026cites this paper
• Free flap salvage via direct urokinase injection into thrombosed veins: a case report

  2025cites this paper
• Review-based development of a protocol for intraoperative urokinase in free flap salvage

  2023cites this paper
• Evaluation of Drugs and Strategies for Treating Coronary Artery Ectasia: Update and Future Perspective

  2022cites this paper
• Rapid Resolution of Pulmonary Thromboemboli in Man

  2017cites this paper
• Pharmacokinetic Properties of Anisoylated Plasminogen Streptokinase Activator Complex and Other Thrombolytic Agents in Animals and in Humans

  2012cites this paper
• Antithrombotic Drugs: Part I

  2012cites this paper
• Antithrombotic Drugs: Part II

  2012cites this paper
• Thrombolytic Therapy in Acute Myocardial Infarction

  2012cites this paper
• Pulmonary Embolism: Current Therapeutic Concepts

  2012cites this paper
• Anticoagulant and Thrombolytic Drugs I: Patho-Physiological and Pharmacological Aspects

  2012cites this paper
• FIBRINOLYTIC ACTIVITY IN HUMAN ISOLATED GLOMERULI

  2010cites this paper
• Laboratory evaluation of the methods of urokinase administration for patients of acute myocardial infarction and cerebral thromboembolic disease . A second report

  2010cites this paper
• Biochemical evaluation of low dose of urokinase in acute myocardial infarction. A double-blind study.

  2009cites this paper
• Uronase as a Clot Lysis Agent for Acute Throm boembolism in the Lower Extremities

  2008cites this paper
• A review of stereotaxy and lysis for intracranial hemorrhage

  2008cites this paper
• Evaluation of a Standard Dosage Schedule with Streptokinase

  2005cites this paper
• Evaluation of a Standard Dosage Schedule with Streptokinase

  2005cites this paper
• Mechanisms of Thrombolysis

  2005cites this paper
• Mechanisms of Thrombosis and thrombolysis

  2004cites this paper
• T H E CONVERSION OF CqS TO C' I ESTERASE BY PLASMIN AND TRYPSIN* BY OSCAR D. RATNOFF,~

  2003cites this paper
• The Fibrinolytic System and Thrombolytic Agents

  2001cites this paper
• Streptokinase and Anisoylated Lys-Plasminogen Streptokinase Activator Complex

  2001cites this paper
• Urokinase and Single-Chain Urokinase-Type Plasminogen Activator (Pro-urokinase)

  2001cites this paper
• Thrombolytische Therapie der venösen Thrombose

  1999cites this paper
• Interventional use of plasminogen activators in central nervous system diseases.

  1998cites this paper
• Thrombolytic agents - An updated overview

  1998cites this paper
• Trends and Future Developments in the Pharmacological Treatment of Acute Ischaemic Stroke

  1997cites this paper
• Biochemistry, Pharmacokinetics, and Dynamics of Single- and Two- Chain Urokinase

  1997cites this paper
• A Historical Review of Hemostasis, Thrombosis, and Antithrombotic Therapy

  1997cites this paper
• Thrombolytic agents--an overview.

  1996cites this paper
• Medical therapy for ischemic stroke.

  1996cites this paper
• Thromboelastographic Study of Fibrinolytic Agents

  1995cites this paper
• The Fibrinolytic System: from Petri Dishes to Genetic Engineering

  1995cites this paper
• Fibrinolysis and its Relevance to Acute Focal Cerebral Ischemia

  1995cites this paper
• Intrapleural fibrinolytic treatment of multiloculated thoracic empyemas.

  1994cites this paper
• Fragmentation Pattern of Fibrinogen During Thrombolysis in Acute Myocardial Infarction with Fibrin-Specific Plasminogen Activators - Detection of High-Molecular Weight Fibrinogen Degradation Products

  1994cites this paper
• Biochemical Pharmacology of Blood and Bloodforming Organs

  1992cites this paper
• Anticoagulants, Antithrombotic and Thrombolytic Agents

  1992cites this paper
• New developments in thrombolytic therapy.

  1992cites this paper
• Thrombosis, fibrinolysis, and thrombolytic therapy: a perspective.

  1991cites this paper
• Antithrombotic Effects of Combining Activated Protein C and Urokinase in Nonhuman Primates

  1991cites this paper
• Thrombolytic intervention in acute thrombotic and embolic stroke.

  1991cites this paper
• Thrombolytic Intervention in Acute Thrombotic and Embolic Stroke

  1991cites this paper
• Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction.

  1991cites this paper
• A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor.

  1991cites this paper
• Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

  1991cites this paper
• Development of new thrombolytic agents using recombinant DNA technology.

  1990cites this paper
• Biochemical characteristics of fibrolase, a fibrinolytic protease from snake venom.

  1990cites this paper
• [New thrombolytic drugs].

  1990cites this paper
• Plasminogen activators: pharmacology and therapy.

  1990cites this paper
• Thrombolytic agents in the treatment of stroke.

  1990cites this paper
• The role of thrombolytic therapy in surgical practice

  1989cites this paper
• Plasminogen Activators: The Old and the New

  1989cites this paper
• Comparison of fibrinolytic and amidolytic methods for the measurement of streptokinase pharmacokinetics in patients with acute myocardial infarction

  1989cites this paper
• The origin of thrombolytic therapy.

  1989cites this paper
• Evaluation of Fibrinolytic Capacity in Plasma during Thrombolytic Therapy with Single (scu-PA) or Two-chain Urokinase Type Plasminogen Activator (tcu-PA) by a Combined Assay System for Urokinase Type Plasminogen Activator Antigen and Function

  1989cites this paper
• Thrombolytic therapy. A review (Part 1 of 2).

  1989cites this paper
• Long-term effect of urokinase therapy in IgA nephropathy.

  1989cites this paper
• Inhibition in Purified Systems and in Human Plasma of Chimaeric Plasminogen Activators Consisting of the NH2-Terminal Region of Tissue-Type Plasminogen Activator and the COOH-Terminal Region of UrokinaseType Plasminogen Activator

  1988cites this paper
• Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial.

  1988cites this paper
• Thrombolytic Therapy: Current Status

  1988cites this paper
• Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function.

  1988cites this paper
• Thrombolytic therapy: current status (1).

  1988cites this paper
• Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).

  1988cites this paper
• Pharmacodynamic and Systemic Fibrinolytic Effects of Plasminogen Activators in Man

  1988cites this paper
• Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.

  1988cites this paper
• Unresolved clinical pharmacologic questions in thrombolytic therapy for acute myocardial infarction.

  1988cites this paper
• Plasminogen activation: biochemistry, physiology, and therapeutics.

  1988cites this paper
• Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy.

  1987cites this paper
• Measurement of human urokinase activity in plasma by using mono-specific antibody-conjugated paper disk.

  1987cites this paper
• The fibrinolytic system and its pharmacologic activation for thrombolysis.

  1987cites this paper
• The preparation and properties of novel reversible polymer‐protein conjugates 2‐ω‐Methoxypolyethylene (5000) glycoxymethylene‐3‐methylmaleyl conjugates of plasminogen activators

  1987cites this paper
• Adverse Reactions to Thrombolytic Agents

  1987cites this paper
• Encapsulation of human urokinase in rabbit erythrocytes and its disposition in the circulation system in rabbits.

  1987cites this paper
• Controlled Trial of Combined Urokinase and Dextran Sulfate Therapy in Patients With Acute Cerebral Infarction

  1986cites this paper
• Pharmacology of thrombolytic drugs.

  1986cites this paper
• The hematologic consequences of thrombolytic therapy.

  1986cites this paper
• Lysis of intraventricular blood clot with urokinase in a canine model: Part 2. In vivo safety study of intraventricular urokinase.

  1986cites this paper
• In Vitro Comparison of Fibrinolytic Activity of Plasminogen Activators Using a Thrombelastographic Method: In Vivo Evaluation of the B-Chain-Streptokinase Complex in the Dog Model Using Pre-Titered Doses

  1986cites this paper
• The fibrinolytic system in man.

  1986cites this paper
• Thrombolytic therapy in the eighties.

  1986cites this paper
• Chapter 11. Plasminogen Activators

  1985cites this paper
• Blood Coagulation and Fibrinolysis

  1985cites this paper
• The current and future use of thrombolytic therapy.

  1985cites this paper
• Assessment of Coronary Artery Disease and Myocardial Ischemia by Invasive Methods

  1985cites this paper
• The fibrinolytic system of the vascular wall.

  1985cites this paper
• Plasminogen activators, tissue degradation, and cancer.

  1985cites this paper
• Urokinase treatment for arteriovenous fistulae declotting in dialyzed patients.

  1984cites this paper
• Coronary thrombolysis: pharmacological considerations with emphasis on tissue-type plasminogen activator (t-PA).

  1984cites this paper
• Outcome of Treatment of Deep-Vein Thrombosis with Urokinase: Relationship to Dosage, Duration of Therapy, Age of the Thrombus and Laboratory Changes

  1984cites this paper
• Toxicological assessment of the hemostatic system, regulatory requirements, and industry practice.

  1984cites this paper
• Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – II. Turnover of Natural and Recombinant Urokinase in Rabbits and Squirrel Monkeys

  1984cites this paper
• Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase.

  1984cites this paper
• An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.

  1984cites this paper
• Systemic Fibrinolytic Activity and Inhibitor Levels During Treatment of Deep Vein Thrombosis with Urokinase and Streptokinase

  1983cites this paper
• Laboratory control of urokinase therapy at low or moderate dosages. An in-vitro study.

  1983cites this paper
• Coronary artery thrombosis: historical aspects.

  1983cites this paper
• Practical use of Anticoagulants

  1983cites this paper
• Purification of Urokinase from Complex Mixtures Using Immobilized Monoclonal Antibody Against Urokinase Light Chain

  1983cites this paper